title: A two dose combined hepatitis A and B vaccine in Chinese youngsters.
abstract: This open, randomized study was conducted in healthy Chinese youngsters, aged between 10 and 19 years to compare the reactogenicity and immunogenicity of two vaccines: the combined vaccine against hepatitis A and B was administered in a two-dose schedule with the profile of the corresponding monovalent vaccines, while the concomitant vaccine was administered also on a two-dose schedule but simultaneously in opposite arms. All vaccinees had antibodies against hepatitis A (anti-HAV) after the 2-dose administration, whereas all but four in the first and two in the second group had protective titres against hepatitis B (anti-HBs). At month 7, the geometric mean titres for both antibodies were more than double for the group of subjects receiving the combined vaccine: 3,701 vs. 1,705 mIU/ml for the anti-HAV, and 1,524 vs. 720 mIU/ ml for the anti-HBs response. Injection site pain was the most commonly reported local symptom and headache was the most reported general symptom. It is concluded that this combined vaccine against hepatitis A and B, administered according to a two-dose schedule, is well-tolerated and highly immunogenic.
authors.affiliation: Department of Medicine, Veterans General Hospital-Taipei, Taiwan, ROC. sdlee@vghtpe.gov.tw
authors.forename: S D
authors.initials: SD
authors.lastname: Lee
authors.forename: C Y
authors.initials: CY
authors.lastname: Chan
authors.forename: M I
authors.initials: MI
authors.lastname: Yu
authors.forename: Y J
authors.initials: YJ
authors.lastname: Wang
authors.forename: F Y
authors.initials: FY
authors.lastname: Chang
authors.forename: K J
authors.initials: KJ
authors.lastname: Lo
authors.forename: A
authors.initials: A
authors.lastname: Safary
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005240:Feasibility Studies; D005260:Female; D006506:Hepatitis A / Q000517:prevention & control*; D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies / Q000097:blood; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology; D006507:Hepatovirus / Q000276:immunology; D006801:Humans; D008297:Male; D013624:Taiwan; D017778:Vaccines, Combined; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D017778:Vaccines, Combined; D014761:Viral Hepatitis Vaccines